Genentech co-pay programs provide financial assistance to eligible commercially insured patients to help with their co-pays, co-insurance, or other out-of-pocket (OOP) costs.
- ACTEMRA® (tocilizumab)
CO-PAY PROGRAM - CELLCEPT® (mycophenolate mofetil)
CO-PAY PROGRAM - ENSPRYNG® (satralizumab-mwge)
CO-PAY PROGRAM - ESBRIET® (pirfenidone)
CO-PAY PROGRAM - EVRYSDI® (risdiplam)
CO-PAY PROGRAM - HEMLIBRA® (emicizumab-kxwh)
CO-PAY PROGRAM - NUTROPIN AQ® (somatropin) injection for subcutaneous use CO-PAY PROGRAM
- OCREVUS® (ocrelizumab)
CO-PAY PROGRAM - PiaSky™ (crovalimab-akkz)
CO-PAY PROGRAM - PULMOZYME® (dornase alfa) Inhalation Solution CO-PAY PROGRAM
- RITUXAN® (rituximab)
IMMUNOLOGY CO-PAY PROGRAM - XOLAIR® (omalizumab) for subcutaneous use CO-PAY PROGRAM
- ALECENSA® (alectinib)
- AVASTIN® (bevacizumab)
- COLUMVI™ (glofitamab-gxbm)
- COTELLIC® (cobimetinib)
- ERIVEDGE® (vismodegib)
- GAZYVA® (obinutuzumab)
- HERCEPTIN® (trastuzumab)
- HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
- KADCYLA® (ado-trastuzumab emtansine)
- LUNSUMIO™ (mosunetuzumab-axgb)
- PERJETA® (pertuzumab)
- PHESGO® (pertuzumab, trastuzumab, and hyaluronidase- zzxf) injection, for subcutaneous use
- POLIVY™ (polatuzumab vedotin-piiq)
- RITUXAN® (rituximab)
- RITUXAN HYCELA® (rituximab/hyaluronidase human)
- ROZLYTREK™ (entrectinib)
- TECENTRIQ® (atezolizumab)
- TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
- VENCLEXTA® (venetoclax tablets)
- ZELBORAF® (vemurafenib)
- LUCENTIS® (ranibizumab injection)
- SUSVIMO™ (ranibizumab injection)
- VABYSMO™ (faricimab-svoa)
Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.